NASDAQ:MBRX
Moleculin Biotech, Inc.
- Stock
Last Close
5.07
17/05 20:00
Market Cap
16.24M
Beta: 2.00
Volume Today
8.36K
Avg: 244.71K
PE Ratio
−0.62
PFCF: −0.65
Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|---|
net income | -3.93M - | -9.80M 149.72% | -11.88M 21.12% | -13.21M 11.19% | -17.36M 31.43% | -15.89M 8.42% | -29.02M 82.62% | -29.77M 2.56% | |
depreciation and amortization | 6.16K - | 18K 192.11% | 68K 277.78% | 199K 192.65% | 200K 0.50% | 164K 18% | 130K 20.73% | 127K 2.31% | |
deferred income tax | -1.39M - | -4.06M - | -2.34M 42.41% | -6.73M 187.52% | |||||
stock based compensation | 411.47K - | 707K 71.82% | 1.14M 61.24% | 1.54M 34.82% | 1.68M 9.30% | 2.37M 41.25% | 2.27M 4.13% | 1.98M 12.79% | |
change in working capital | -256.18K - | 542K 311.57% | 1.61M 197.05% | -2.14M 233.04% | -41K 98.09% | 1.04M 2,631.71% | 224K 78.42% | 403K 79.91% | |
accounts receivables | |||||||||
inventory | |||||||||
accounts payables | -41.13M - | 411K 101.00% | 436K 6.08% | 907K 108.03% | -1.02M 212.90% | 235K 122.95% | 731K 211.06% | 403K 44.87% | |
other working capital | 40.87M - | 131K 99.68% | 1.17M 796.18% | -3.05M 359.71% | 983K 132.24% | 803K 18.31% | -507K 163.14% | -403K 20.51% | |
other non cash items | 2.60M - | -3.15M 220.92% | 476K 115.14% | 85K 82.14% | 96K 12.94% | -1.24M 1,394.79% | 3.56M 386.16% | ||
net cash provided by operating activities | -3.76M - | -7.32M 94.53% | -12.20M 66.62% | -17.20M 40.93% | -17.77M 3.33% | -18.95M 6.64% | -27.64M 45.84% | -24.10M 12.80% | |
investments in property plant and equipment | -21.47K - | -28K 30.41% | -417K 1,389.29% | -52K 87.53% | -376K 623.08% | -19K 94.95% | -67K 252.63% | -124K 85.07% | |
acquisitions net | -99.64K - | 1K - | 2K 100% | ||||||
purchases of investments | |||||||||
sales maturities of investments | |||||||||
other investing activites | |||||||||
net cash used for investing activites | -121.11K - | -28K 76.88% | -417K 1,389.29% | -51K 87.77% | -374K 633.33% | -19K 94.92% | -67K 252.63% | -124K 85.07% | |
debt repayment | -469.94K - | ||||||||
common stock issued | 9.17M - | 6.07M 33.80% | 12.03M 98.07% | 19.29M 60.43% | 22.56M 16.94% | 74.68M 231.03% | 4.17M - | ||
common stock repurchased | -17 - | -23 35.29% | -23 0% | 772K 3,356,621.74% | |||||
dividends paid | |||||||||
other financing activites | 165K - | 3.99M 2,316.97% | 20K 99.50% | 1.56M 7,710.00% | -11.98K 100.77% | 40.02K 434.00% | -22.98K 157.41% | -287K 1,149.08% | |
net cash used provided by financing activities | 8.87M - | 10.06M 13.47% | 12.04M 19.74% | 20.85M 73.13% | 22.55M 8.13% | 74.72M 231.38% | -23K 100.03% | 4.65M 20,321.74% | |
effect of forex changes on cash | -5K - | -4K 20% | 34K 950% | -24K 170.59% | -29K 20.83% | -21K 27.59% | |||
net change in cash | 4.98M - | 2.71M 45.63% | -580K 121.43% | 3.60M 720.86% | 4.44M 23.24% | 55.73M 1,155.75% | -27.76M 149.81% | -19.59M 29.41% | |
cash at beginning of period | 28.09K - | 5.01M 17,724.21% | 7.71M 54.06% | 7.13M 7.52% | 10.73M 50.48% | 15.17M 41.34% | 70.90M 367.30% | 43.15M 39.15% | |
cash at end of period | 5.01M - | 7.71M 54.06% | 7.13M 7.52% | 10.73M 50.48% | 15.17M 41.34% | 70.90M 367.30% | 43.15M 39.15% | 23.55M 45.42% | |
operating cash flow | -3.76M - | -7.32M 94.53% | -12.20M 66.62% | -17.20M 40.93% | -17.77M 3.33% | -18.95M 6.64% | -27.64M 45.84% | -24.10M 12.80% | |
capital expenditure | -21.47K - | -28K 30.41% | -417K 1,389.29% | -52K 87.53% | -376K 623.08% | -19K 94.95% | -67K 252.63% | -124K 85.07% | |
free cash flow | -3.79M - | -7.35M 94.17% | -12.62M 71.65% | -17.25M 36.69% | -18.15M 5.20% | -18.97M 4.54% | -27.71M 46.05% | -24.23M 12.56% |
All numbers in USD (except ratios and percentages)